Anticancer activity of a trans-platinum(II) complex of 3-aminoflavone to ovarian cancer cells.
Cisplatin is a classical anticancer drug used in the treatment of ovarian cancer. Unfortunately, the treatment is associated with numerous adverse effects. Studies concerning new platinum derivatives with less organ toxicity are conducted. The aim of this study was to analyse the effect of a new trans-platinum(II) complex of 3-aminoflavone on the viability and mortality of the cells from OVCAR 3 and CAOV 3 ovarian cancer cell lines and on the expression of the selected genes involved in the process of apoptosis.



The viability of ovarian cancer cells and the cytotoxicity of a trans-platinum(II) complex of 3-amino-flavone: [trans-Pt(3-af )₂Cl₂), trans-bis-(3-aminoflavone) dichloridoplatinum(II)] and cisplatin were analysed using a spectrophotometric method with the use of MTT assay and LDH assay. BAX, BCL2, BIRC5 gene expression analysis on mRNA level was conducted with the use of Real-Time PCR method.



It was observed that parallel to an increase in the concentration of the new complex compound and cisplatin there is a decrease in viability and an increase in mortality of ovarian cancer cells. As a result of exposure to the studied compound and cisplatin, an increased BAX gene expression and decreased BCL2 and BIRC5 gene expression were observed in the studied ovarian cancer cell lines.



Trans-Pt(3-af )₂Cl₂ exhibits anticancer activity towards OVCAR 3 and CAOV 3 ovarian cancer cell lines. The studied complex compound can be considered as a potential anticancer drug.
Department of Applied Pharmacy, Medical University of Warsaw, Poland. magdalena.orzechowska@wum.edu.pl.
Magdalena
M
Orzechowska
Małgorzata
M
Fabijańska
Justyn
J
Ochocki
Maciej
M
Małecki
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D005260:Female; D005419:Flavonoids / Q000494:pharmacology*; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000187:drug effects / Q000235:genetics; D007770:L-Lactate Dehydrogenase / Q000187:drug effects / Q000378:metabolism; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000235:genetics*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects / Q000235:genetics; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077022:Survivin; D051028:bcl-2-Associated X Protein / Q000187:drug effects / Q000235:genetics
C488624:3-aminoflavone; D000970:Antineoplastic Agents; C494826:BAX protein, human; C000595707:BCL2 protein, human; C107489:BIRC5 protein, human; D005419:Flavonoids; D051034:Inhibitor of Apoptosis Proteins; D009944:Organoplatinum Compounds; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; D000077022:Survivin; D051028:bcl-2-Associated X Protein; D007770:L-Lactate Dehydrogenase; D002945:Cisplatin
CAOV 3; OVCAR 3; Trans-Pt(3-af )2Cl2; apoptosis; cisplatin; ovarian cancer; viability